Trexquant Investment LP Seres Therapeutics, Inc. Transaction History

Trexquant Investment LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$2.7 - $7.62 $47,841 - $135,018	-17,719 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$6.3 - $8.84 $240,137 - $336,954	-38,117 Reduced 68.27%	17,719 $126,000
Q4 2021 Feb 14, 2022	BUY	$6.02 - $11.43 $229,325 - $435,414	38,094 Added 214.71%	55,836 $465,000
Q3 2021 Nov 12, 2021	BUY	$5.46 - $22.6 $96,871 - $400,969	17,742 New	17,742 $123,000
Q2 2021 Aug 12, 2021	SELL	$18.46 - $24.36 $253,621 - $334,682	-13,739 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$17.66 - $28.92 $15,894 - $26,028	-900 Reduced 6.15%	13,739 $283,000
Q4 2020 Feb 11, 2021	BUY	$23.25 - $37.73 $340,356 - $552,329	14,639 New	14,639 $359,000
Q3 2020 Nov 06, 2020	SELL	$3.74 - $28.74 $249,753 - $1.92 Million	-66,779 Closed	0 $0
Q2 2020 Aug 07, 2020	BUY	$3.04 - $6.2 $203,008 - $414,029	66,779 New	66,779 $318,000
Q1 2018 May 03, 2018	SELL	$7.34 - $11.16 $104,962 - $159,588	-14,300 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$9.15 - $12.64 $130,845 - $180,752	14,300	14,300 $145,000

46.3M

119K

466K

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $114M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.